2020
Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym
Longo D, Shoda L, Howell B, Coric V, Berman R, Qureshi I. Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym. Toxicological Sciences 2020, 175: 292-300. PMID: 32040174, PMCID: PMC7253195, DOI: 10.1093/toxsci/kfaa019.Peer-Reviewed Original ResearchConceptsOral tabletsALT elevationLiver toxicityClinical dataFirst-pass liver metabolismLiver function test parametersFirst-pass hepatic metabolismLiver toxicity riskAlanine transaminase levelsRelative risk reductionLower overall doseAmyotrophic lateral sclerosisALT levelsTransaminase levelsLiver exposureSublingual formulationHepatic metabolismLateral sclerosisRiluzoleLiver metabolismULNInterindividual variabilityOverall doseHepatotoxicity potentialOxidative stress
1999
A prospective, community‐based evaluation of liver enzymes in individuals with hepatitis C after drug use
Inglesby T, Rai R, Astemborski J, Gruskin L, Nelson K, Vlahov D, Thomas D. A prospective, community‐based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999, 29: 590-596. PMID: 9918940, DOI: 10.1002/hep.510290219.Peer-Reviewed Original ResearchConceptsSerum ALT levelsALT levelsALT valuesDrug usePrior illicit drug useSerum alanine transaminase levelsAlanine transaminase levelsNormal ALT valuesHepatitis C virusIllicit drug useImportant disease outcomesElevated ALTHepatitis CTransaminase levelsInitial visitLiver biopsyVisit variabilityC virusCommunity-based evaluationLiver enzymesDisease outcomeHCVPatientsMore visitsNatural history
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply